Home > Insider Trading > Filing (0001209191-18-034404)

Filing Details

Accession Number:: 0001209191-18-034404
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-05-31 16:54:17
Reporting Period:: 2018-05-30

Accepted Time:: 2018-05-31 16:54:17
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1659323	Iterum Therapeutics Plc	ITRM	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1340806	K Vijay Lathi	C/O New Leaf Ventures 7 Times Square, Suite 3502 New York NY 10036		No	No	Yes	No
1547100	Liam Ratcliffe	C/O New Leaf Ventures 7 Times Square, Suite 3502 New York NY 10036		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2018-05-30	466,793	$0.00	466,793	No	4	C	Indirect	By New Leaf Ventures III, L.P.
Ordinary Shares	Acquisiton	2018-05-30	178,230	$0.00	645,023	No	4	C	Indirect	By New Leaf Ventures III, L.P.
Ordinary Shares	Acquisiton	2018-05-30	148,603	$0.00	793,626	No	4	C	Indirect	By New Leaf Ventures III, L.P.
Ordinary Shares	Acquisiton	2018-05-30	278,062	$13.00	1,071,688	No	4	P	Indirect	By New Leaf Ventures III, L.P.
Ordinary Shares	Acquisiton	2018-05-30	384,615	$13.00	384,615	No	4	P	Indirect	By New Leaf Biopharma Opportunities II, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By New Leaf Ventures III, L.P.
No	4	C	Indirect	By New Leaf Ventures III, L.P.
No	4	C	Indirect	By New Leaf Ventures III, L.P.
No	4	P	Indirect	By New Leaf Ventures III, L.P.
No	4	P	Indirect	By New Leaf Biopharma Opportunities II, L.P.

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Series A Preferred Shares	Disposition	2018-05-30	466,793	$0.00	466,793	$0.00
Ordinary Shares	Series B-1 Preferred Shares	Disposition	2018-05-30	178,230	$0.00	178,230	$0.00
Ordinary Shares	Series B-2 Preferred Shares	Disposition	2018-05-30	148,603	$0.00	148,603	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration.
These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any.
The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration.
The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration.
These shares are held directly by New Leaf Biopharma Opportunities II, L.P. ("NBPO-II"). New Leaf BPO Associates II, L.P. ("NBPO-IIA") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. ("NBPO-IIM") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NBPO-II. The Managing Directors are the managing directors of NBPO-IIM and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NBPO-II. The Managing Directors, NBPO-IIA and NBPO-IIM each disclaim Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of their respective pecuniary interest therein, if any.
Not applicable.